GBE50 Attenuates Inflammatory Response by Inhibiting the p38 MAPK and NF-κB Pathways in LPS-Stimulated Microglial Cells

Figure 3

The effect of GBE50 on TNF-α and IL-1β in BV2 cells activated by LPS. (a) The effect of GBE50 on TNF-α in BV2 cells activated by LPS. GBE50 significantly reduced TNF-α at doses of 10 and 100 μg/mL. (b) The effect of GBE50 on IL-1β in BV2 cells activated by LPS, GBE50 significantly reduced IL-1β at doses of 10 and 100 μg/mL. *𝑃<0.05, **𝑃<0.01 versus control and ^#𝑃<0.05, ^##𝑃<0.01 versus LPS group.

(a)

(b)